Nyilas, Margaretta
Otsuka (United States) · Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)
3 papers on CoChat
Most cited papers
- Verified
Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry
Treatment of Major DepressionSchizophrenia research and treatment
Cited by 182
- Verified
Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study
Calabrese, J. R., Sanchez, R., Jin, N., Amatniek, J., Cox, K., Johnson, B., Perry, P., Hertel, P., Such, P., Salzman, P. M., et al. (2017) · The Journal of Clinical Psychiatry
Bipolar Disorder and TreatmentSchizophrenia research and treatment
Cited by 135
- Verified
Aripiprazole for the treatment of pediatric bipolar I disorder: a 30‐week, randomized, placebo‐controlled study
Findling, R. L., Correll, C. U., Nyilas, M., Forbes, R. A., McQuade, R. D., Jin, N., Ivanova, S., Mankoski, R., Carson, W. H., & Carlson, G. A. (2013) · Bipolar Disorders
Bipolar Disorder and TreatmentSchizophrenia research and treatment
Cited by 121
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free